InsiderSignal.AI

InsiderSignal.ai

DVAX - Dynavax Technologies Corp

Insider Purchase by Myers Scott Dunseth (Dir)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, Myers Scott Dunseth, serving as Dir at Dynavax Technologies Corp (DVAX), purchased 3,800 shares at $10.82 per share, for a total transaction value of $41,116.00. Following this transaction, Myers Scott Dunseth now holds 35,004 shares of DVAX.

This purchase represents a 12.00% increase in Myers Scott Dunseth's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, August 22, 2025 and publicly disclosed via SEC Form 4 filing on Monday, August 25, 2025, 3 days after the trade was made.

Dynavax Technologies Corp operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Myers Scott Dunseth

Dir

Scott Dunseth Myers is the Chairperson of the Board of Directors at Dynavax Technologies Corporation (DVAX), a position he has held since October 2021.[[4]](https://www.dynavax.com/about/) On August 22, 2025, he purchased 3,800 shares of DVAX common stock at $10.82 per share in an open-market transaction, increasing his direct ownership to 35,004 shares.[[3]](https://www.stocktitan.net/sec-filings/DVAX/form-4-dynavax-technologies-corporation-insider-trading-activity-03aab40546c9.html)[[1]](https://www.itiger.com/news/2562024462)[[2]](https://www.tipranks.com/news/insider-trading/director-makes-bold-move-with-major-dynavax-stock-purchase-insider-trading) Mr. Myers brings nearly three decades of experience in the global pharmaceutical and medical technology sectors. His career highlights include serving as Chief Executive Officer and President of Viridian Therapeutics in 2023, leading AMAG Pharmaceuticals as CEO through its turnaround and sale to Covis Pharmaceuticals in 2020, and heading Rainier Therapeutics as Chairperson and CEO prior to its asset sale to Fusion Pharmaceuticals.[[4]](https://www.dynavax.com/about/) He was also CEO, President, and Director at Cascadian Therapeutics until its acquisition by Seagen in 2018, and has held board roles at companies including Zentalis Pharmaceuticals, Harpoon Therapeutics, and Cartesian Therapeutics.[[4]](https://www.dynavax.com/about/)[[5]](https://www.gurufocus.com/insider/30818/scott-dunseth-myers) Mr. Myers holds a B.A. in Biology from Northwestern University and an M.B.A. from the University of Chicago Booth School of Business.[[4]](https://www.dynavax.com/about/)

View full insider profile →

Trade Price

$10.82

Quantity

3,800

Total Value

$41,116.00

Shares Owned

35,004

Trade Date

Friday, August 22, 2025

184 days ago

SEC Filing Date

Monday, August 25, 2025

Filed 3 days after trade

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About Dynavax Technologies Corp

Company Overview

No company information available
View news mentioning DVAX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/153520

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime